Growth Metrics

Novartis Ag (NVS) Long-Term Deferred Tax (2016 - 2026)

Novartis Ag's Long-Term Deferred Tax history spans 12 years, with the latest figure at $600.0 million for Q1 2026.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $600.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $600.0 million, a N/A change, with the full-year FY2025 number at $5.4 billion, up 1069.46% from a year prior.
  • Long-Term Deferred Tax hit $600.0 million in Q1 2026 for Novartis Ag, down from $5.4 billion in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for NVS hit a ceiling of $5.4 billion in Q4 2025 and a floor of $34.0 million in Q4 2023.
  • Historically, Long-Term Deferred Tax has averaged $2.2 billion across 5 years, with a median of $661.0 million in 2023.
  • Biggest five-year swings in Long-Term Deferred Tax: crashed 99.09% in 2023 and later soared 1267.65% in 2024.
  • Tracing NVS's Long-Term Deferred Tax over 5 years: stood at $3.7 billion in 2022, then crashed by 99.09% to $34.0 million in 2023, then soared by 1267.65% to $465.0 million in 2024, then skyrocketed by 1069.46% to $5.4 billion in 2025, then crashed by 88.97% to $600.0 million in 2026.
  • Business Quant data shows Long-Term Deferred Tax for NVS at $600.0 million in Q1 2026, $5.4 billion in Q4 2025, and $5.2 billion in Q2 2025.